Alembic Pharma
Ticker > Company >

Alembic Pharma share price

Alembic Pharmaceuticals Ltd.

NSE: APLLTD BSE: 533573 SECTOR: Pharmaceuticals & Drugs  175k   936   155

968.70
-3.20 (-0.33%)
NSE: Today, 09:54 AM

Price Summary

Today's High

₹ 979.6

Today's Low

₹ 965.1

52 Week High

₹ 1303.9

52 Week Low

₹ 725.2

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 19041.07 Cr.

Enterprise Value

₹ 20162.45 Cr.

No. of Shares

19.66 Cr.

P/E

37.85

P/B

3.67

Face Value

₹ 2

Div. Yield

1.13 %

Book Value (TTM)

₹  264.28

CASH

₹ 20.84 Cr.

DEBT

₹ 1142.22 Cr.

Promoter Holding

69.67 %

EPS (TTM)

₹  25.6

Sales Growth

2.7%

ROE

9.96 %

ROCE

11.74%

Profit Growth

-24.51 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Alembic Pharmaceuticals Ltd.

Azithral TELLZY ZEET Elena Corazon MEGACARE ZENOM CORIUM GASTRON ENTERON Maxis Ouron

Index Presence

The company is present in 18 Indices.

NFTSML250MOMQ100

Nifty Smallcap250 Momentum Quality 100 index
48043.05
  106 (0.221123327363704%)

NFTMIDSMLHEALTH

Nifty MidSmall Healthcare
42745.3
  232 (0.545711577318153%)

NIFTY500

Nifty 500
23382.05
  85.2000000000007 (0.365714678164641%)

NIFTYMIDSMALL400

Nifty MidSmallcap 400
20169.2
  12.6500000000015 (0.0627587558386766%)

NIF500LGMIDSML

Nifty500 LargeMidSmall Equal-Cap Weighted Index
18014.75
  36.2000000000007 (0.201351054451004%)

NIFTYSMALLCAP250

Nifty Smallcap 250
17470
  14.4000000000015 (0.0824950159261206%)

NY500MUL50:25:25

Nifty500 Multicap 50:25:25
16319.7
  44 (0.270341675012431%)

NFT500EQUAL

Nifty 500 Equal Weight
14424.3
  19.25 (0.133633690962554%)

NIFTYTOTALMCAP

Nifty Total Market index
13157.95
  47 (0.358478981309518%)

SMLCAP

S&P Bse Small Cap
53971.61
  74.3600000000006 (0.137966222766472%)

BSE HC

S&P Bse Healthcare
43668.39
  76.989999999998 (0.17661740618562%)

BSE500

S&P Bse 500
36676.55
  131.530000000006 (0.359912239752513%)

S&P MIDSMLCAP

S&P Bse MidSmallCap
12414.1
  73.2299999999996 (0.593394144821224%)

MSL400

S&P Bse 400 MidSmallCap
12153.46
  1.6299999999992 (0.0134136175374389%)

BSE1000

Bse 1000
10923.22
  37.9799999999996 (0.348912839772009%)

ALLCAP

S&P Bse Allcap
10130.99
  38.3799999999992 (0.380278243189802%)

SHA500

S&P Bse 500 Shariah
9113.66
  125.5 (1.39628133010539%)

SML250

S&P Bse 250 SmallCap
6982.48
  9.78999999999996 (0.140404922633874%)

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year2.7%
3 Year6.21%
5 Year7.86%

Profit Growth

1 Year-24.51%
3 Year-2.54%
5 Year-12.29%

ROE%

1 Year9.96%
3 Year10.47%
5 Year13.56%

ROCE %

1 Year11.74%
3 Year11.19%
5 Year14.14%

Debt/Equity

0.2199

Price to Cash Flow

84.04

Interest Cover Ratio

8.9585

CFO/PAT (5 Yr. Avg.)

1.16059649856483

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2025 69.67 0.00
Dec 2024 69.61 0.00
Sep 2024 69.61 0.00
Jun 2024 69.61 0.00
Mar 2024 69.61 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has a healthy Interest coverage ratio of 8.9585.
  • The company has an efficient Cash Conversion Cycle of 48.8805 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.16059649856483.
  • The company has a high promoter holding of 69.67%.

 Limitations

  • The company has shown a poor profit growth of -2.54352612661289% for the Past 3 years.
  • The company has shown a poor revenue growth of 6.20801932155517% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
Net Sales 1474.55 1475.56 1580.35 1406.09 1570.64
Total Expenditure 1186.36 1184.13 1320.86 1226.26 1399.98
Operating Profit 288.19 291.43 259.49 179.83 170.66
Other Income 7.22 3.14 16.06 15.46 13.21
Interest 10.13 12.69 18.28 21.79 23.71
Depreciation 69.12 68.68 70.12 69.69 68.6
Exceptional Items 0 0 12.87 0 0
Profit Before Tax 216.16 213.2 200.02 103.81 91.56
Tax 14.29 37.01 34.24 18 16.22
Profit After Tax 201.87 176.19 165.78 85.81 75.34
Adjusted EPS (Rs) 10.27 8.96 8.43 4.37 3.83

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 5066.88 5035.4 5149 5874.06 6032.63
Total Expenditure 3617.71 4126.63 4484.97 4876.27 5136.55
Operating Profit 1449.17 908.77 664.03 997.79 896.08
Other Income 84.08 51.17 3.85 32.05 53.19
Interest 12.98 17.02 49 54.47 76.47
Depreciation 182.53 284.92 272.95 271.14 277.08
Exceptional Items 0 0 0 0 12.87
Profit Before Tax 1337.74 658 345.93 704.23 608.59
Tax 241.2 114.45 -0.8 37.75 105.47
Net Profit 1096.54 543.55 346.73 666.48 503.12
Adjusted EPS (Rs.) 55.79 27.65 17.64 33.91 25.6

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 39.31 39.31 39.31 39.31 39.31
Total Reserves 5062.5 5251.03 4374.98 4869.6 5155.43
Borrowings 199.89 0 0 0 0
Other N/C liabilities 203.19 204.25 86.67 83.59 84.51
Current liabilities 1378.36 1694.45 1551.3 1368.4 2285.86
Total Liabilities 6883.25 7189.04 6052.26 6360.9 7565.11
Assets
Net Block 1773.82 1771.1 2377.47 2535.66 2513.47
Capital WIP 1944.28 2205.8 601.28 524.36 837.23
Intangible WIP 238.25 98.44 0 0 0
Investments 156.12 219.36 229.27 226.68 259.56
Loans & Advances 36.4 34.88 64.03 44.46 102.39
Other N/C Assets 0 0 0 0 0
Current Assets 2734.38 2859.46 2780.21 3029.74 3852.46
Total Assets 6883.25 7189.04 6052.26 6360.9 7565.11
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 1337.74 658.01 345.93 704.23 608.59
Adjustment 92.6 413.35 448.49 284.21 365.07
Changes in Assets & Liabilities 198.56 -397.3 -10.39 -205.64 -701.42
Tax Paid -240.42 -128.8 -53.78 -10.03 -45.67
Operating Cash Flow 1388.48 545.26 730.25 772.77 226.57
Investing Cash Flow -836.65 -368.72 -460.98 -329.02 -636.08
Financing Cash Flow -533.75 -216.64 -261.16 -445.29 403.61
Net Cash Flow 18.08 -40.1 8.11 -1.54 -5.9

Corporate Actions

Investors Details

PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
promoters 69.61 69.61 69.61 69.61 69.67
alembic limited 28.54 28.54 28.54 28.54 28.54
barkha pranav amin 0.03 0.03 0.03 0.03 0.03
chirayu ramanbhai amin 2.13 2.13 2.13 2.13 2.13
chirayu ramanbhai amin hu... - - - - 0.05
gallup trust (pranav chir... 0.05 0.05 0.05 0.05 0.05
inaaya shaunak amin 0.04 0.04 0.04 0.04 0.04
krupa shaunak amin 0.03 0.03 0.03 0.03 0.03
malika chirayu amin 1.53 1.53 1.53 1.53 1.53
naintara shaunak amin 0.04 0.04 0.04 0.04 0.04
nirayu limited 35.63 35.63 35.63 35.63 35.64
pranav chirayu amin 0.51 0.51 0.51 0.51 0.51
ranvir pranav amin 0.02 0.02 0.02 0.02 0.02
samira pranav amin 0.02 0.02 0.02 0.02 0.02
satori trust (chirayu ram... 0.03 0.03 0.03 0.03 0.03
shaunak chirayu amin 0.51 0.51 0.51 0.51 0.51
udit chirayu amin 0.51 0.51 0.51 0.51 0.51
PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
investors 30.39 30.39 30.39 30.39 30.33
dsp midcap fund 3.92 4.20 4.22 4.38 4.60
investor education and pr... - 0.73 - 0.78 0.78
kotak small cap fund 1.76 1.76 1.89 1.77 1.74
life insurance corporatio... 4.33 4.33 4.33 4.32 4.32
llp 0.02 0.02 0.02 0.02 0.01
tata aia life insurance c... - - - - 1.01
investor education and pr... 0.73 - 0.78 - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Alembic Pharmaceuticals gets EIR from USFDA for API-III facility at Karakhadi 18 Jun, 2:51 PM USFDA concludes inspection at Alembic Pharmaceuticals’ Gujarat API-I & II facility 2 Jun, 9:17 AM Alembic Pharmaceuticals receives USFDA's final approval for Bosutinib Tablets 31 May, 12:30 PM Alembic Pharmaceuticals gets USFDA’s nod for Amlodipine and Atorvastatin Tablets 23 May, 3:30 PM Alembic Pharmaceuticals gets USFDA’s final nod for Rivaroxaban Tablets USP 15 May, 2:29 PM Alembic Pharma - Quaterly Results 6 May, 2:10 PM Alembic Pharma - Quaterly Results 6 May, 2:10 PM Alembic Pharma - Quaterly Results 6 May, 2:10 PM Alembic Pharmaceuticals informs about press release 2 May, 5:47 PM Alembic Pharmaceuticals receives USFDA’s final approval for Ticagrelor Tablets 2 May, 5:34 PM Alembic Pharmaceuticals informs about update 26 Apr, 3:54 PM Alembic Pharmaceuticals commissions new manufacturing facility in Madhya Pradesh 26 Apr, 3:20 PM Alembic Pharmaceuticals gets USFDA’s nod for Carbamazepine Tablets 17 Apr, 2:20 PM Alembic Pharmaceuticals informs about press release 17 Apr, 1:12 PM Alembic Pharmaceuticals receives USFDA’s final approval for Pantoprazole Sodium Injection 1 Apr, 4:30 PM Alembic Pharmaceuticals completes USFDA inspection for API-III Facility at Karakhadi 22 Mar, 10:18 AM Alembic Pharmaceuticals informs about updates 22 Mar, 9:03 AM Alembic Pharmaceuticals’ arm incorporates wholly-owned subsidiary in USA 18 Mar, 11:30 AM USFDA concludes inspection at Alembic Pharmaceuticals’ Vadodara facility 10 Mar, 10:07 AM Alembic Pharmaceuticals informs about completion of tenure of independent director 4 Feb, 10:14 AM Alembic Pharma - Quaterly Results 3 Feb, 2:37 PM Alembic Pharma - Quaterly Results 3 Feb, 2:37 PM Alembic Pharma - Quaterly Results 3 Feb, 2:37 PM Alembic Pharma gets USFDA’s approval for Brexpiprazole Tablets 15 Jan, 12:57 PM Alembic Pharmaceuticals gets USFDA’s final approval for Divalproex Sodium Delayed-Release Capsules 20 Dec, 5:42 PM Alembic Pharmaceuticals informs about updates 11 Dec, 3:15 PM Alembic Pharmaceuticals completes ANVISA GMP audit for API-II Facility in Panelav 11 Dec, 3:13 PM Alembic Pharma gets USFDA’s tentative nod for Olopatadine Hydrochloride Ophthalmic Solution 4 Dec, 3:59 PM Alembic Pharmaceuticals informs about details of loss of certificate 2 Dec, 3:03 PM USFDA completes inspection at Alembic Pharmaceuticals’ Solid Oral Formulation Facility 25 Nov, 9:42 AM Alembic Pharma gets USFDA’s final approval for Ivabradine Tablets 12 Nov, 4:00 PM Alembic Pharma gets final nod for Diltiazem Hydrochloride Extended-Release Capsules 11 Nov, 9:17 AM Alembic Pharmaceuticals informs about press release 11 Nov, 9:11 AM Alembic Pharma - Quaterly Results 7 Nov, 1:06 PM Alembic Pharma - Quaterly Results 7 Nov, 1:06 PM Alembic Pharma - Quaterly Results 7 Nov, 1:06 PM Alembic Pharmaceuticals informs about loss of share certificate 23 Oct, 1:38 PM Alembic Pharma gets USFDA approval for Diltiazem Hydrochloride Extended-Release Capsules 21 Oct, 9:30 AM USFDA completes inspection at Alembic Pharmaceuticals’ Oncology formulation facility 9 Oct, 9:50 AM Alembic Pharmaceuticals informs about disclosure 9 Oct, 9:48 AM Alembic Pharmaceuticals gets final nod for Alcaftadine Ophthalmic Solution 4 Oct, 9:49 AM Alembic Pharmaceuticals informs about press release 3 Oct, 10:05 AM Alembic Pharmaceuticals gets USFDA’s final approval for Lamotrigine Extended-Release Tablets 3 Oct, 9:30 AM Alembic Pharmaceuticals gets EIR from USFDA for Oral Solid Formulation Facility 28 Sep, 10:31 AM Alembic Pharmaceuticals gets USFDA’s final approval for Paliperidone Extended-Release tablets 27 Sep, 3:27 PM Alembic Pharmaceuticals gets USFDA’s final approval for Albendazole Tablets 5 Sep, 2:38 PM Alembic Pharmaceuticals gets USFDA’s final approval for Betamethasone Valerate Foam 24 Aug, 4:24 PM Alembic Pharmaceuticals informs about press release 24 Aug, 12:28 PM Alembic Pharmaceuticals gets USFDA’s final approval for Dabigatran Etexilate Capsules 13 Aug, 2:58 PM Alembic Pharmaceuticals reports 12% rise in Q1 consolidated net profit 8 Aug, 4:49 PM

Alembic Pharma Stock Price Analysis and Quick Research Report. Is Alembic Pharma an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Alembic Pharma and its performance over the period of time. Alembic Pharma stock price today is Rs 968.7.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Alembic Pharma cash from the operating activity was Rs 226.57 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Alembic Pharma has a Debt to Equity ratio of 0.2199 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Alembic Pharma , the EPS growth was -24.5107 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Alembic Pharma has OPM of 14.853886281771 % which is a bad sign for profitability.
     
  • ROE: Alembic Pharma have a poor ROE of 9.9592 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Alembic Pharma is Rs 968.7. One can use valuation calculators of ticker to know if Alembic Pharma share price is undervalued or overvalued.
Last Updated on:
Brief about Alembic Pharma

Alembic Pharmaceuticals Ltd Financials: Check Share price, Balance Sheet, Annual report and Quarterly Results for company analysis 

 

Welcome to the stock analysis page for Alembic Pharmaceuticals Ltd., a prominent pharmaceutical company in India. In this comprehensive analysis, we will delve into various aspects of the company, including its share price, balance sheet, annual report, dividend, quarterly results, stock price, price chart, news, concall transcripts, investor presentations, promoters, and shareholders.

Alembic Pharmaceuticals Ltd Share Price

Stay updated on the latest share price of Alembic Pharmaceuticals Ltd. and monitor its performance in the stock market. Ticker provides real-time share price data, allowing you to track the stock's movement and make well-informed investment decisions.

Alembic Pharmaceuticals Ltd Balance Sheet

Gain insights into the balance sheet of Alembic Pharmaceuticals Ltd., an essential financial statement that provides details about the company's assets, liabilities, and shareholders' equity. Utilize ticker premium feature, the DCF Analysis, to calculate the fair value of the company based on its balance sheet.

Alembic Pharmaceuticals Ltd Annual Report

Access the annual reports of Alembic Pharmaceuticals Ltd., which offer a comprehensive overview of the company's performance, achievements, and strategic initiatives. These reports are conveniently available for download on Ticker, enabling you to analyze the company's financials in detail.

Alembic Pharmaceuticals Ltd Dividend

Stay informed about the dividend payouts of Alembic Pharmaceuticals Ltd. to its shareholders. Explore the history of dividends, dividend yield, and dividend payment dates. Ticker pre-built screening tools can assist in identifying stocks with consistent and attractive dividend payouts.

Alembic Pharmaceuticals Ltd Quarterly Results

Analyze Alembic Pharmaceuticals Ltd.'s quarterly results, including revenue, profit, and key financial metrics. Utilize ticker premium features, such as BVPS Analysis, Earnings multiple approach, and DuPont analysis, to gain a deeper understanding of the company's financial performance.

Alembic Pharmaceuticals Ltd Stock Price

Track the historical stock price of Alembic Pharmaceuticals Ltd. using our interactive price charts. Ticker provides customizable charts with various timeframes, technical indicators, and overlays, enabling you to evaluate the stock's performance effectively.

Alembic Pharmaceuticals Ltd Price Chart

Analyze the stock price movements of Alembic Pharmaceuticals Ltd. through ticker user-friendly price chart. Customize the chart to view key trends, patterns, and support/resistance levels that can assist you in making well-informed investment decisions.

Alembic Pharmaceuticals Ltd News

Stay up to date with the latest news and developments related to Alembic Pharmaceuticals Ltd. Ticker platform curates news articles to keep you informed about the company's performance, industry trends, and market dynamics.

Alembic Pharmaceuticals Ltd Concall Transcripts

Explore the concall transcripts of Alembic Pharmaceuticals Ltd., which provide detailed records of the company's conference calls with analysts and investors. Through these transcripts, you can gain valuable insights into the company's future plans, strategies, and overall outlook.

Alembic Pharmaceuticals Ltd Investor Presentations

Access the investor presentations of Alembic Pharmaceuticals Ltd., which offer a comprehensive overview of the company's business model, growth prospects, and investment opportunities. These presentations provide valuable insights into the company's operations and strategic initiatives.

Alembic Pharmaceuticals Ltd Promoters

Learn about the key promoters of Alembic Pharmaceuticals Ltd., the individuals or entities who have played a significant role in establishing and expanding the company. Gain insights into their background, contributions, and shareholding patterns.

Alembic Pharmaceuticals Ltd Shareholders

Understand the shareholder base of Alembic Pharmaceuticals Ltd. and the distribution of ownership among various categories of investors. Analyze the institutional and retail investor participation to gauge market sentiment towards the stock.

Experience the power of comprehensive stock analysis with Alembic Pharmaceuticals Ltd. Ticker provides a range of pre-built screening tools, downloadable annual reports, and real-time stock data to assist you in making informed investment decisions. Start exploring today!

Alembic Pharmaceuticals Ltd ROCE

Return on Capital Employed (ROCE) is a critical financial measure reflecting Alembic Pharmaceuticals Ltd's profitability and efficiency in utilizing its capital investments effectively. Visitors can find the ROCE data for Alembic Pharmaceuticals Ltd in the financials table or ratio section above, gaining valuable insights into how effectively the company generates profits from the capital employed in its operations.

Alembic Pharmaceuticals Ltd EBITDA

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) serves as a key indicator of Alembic Pharmaceuticals Ltd's operational performance and cash flow generation. By excluding interest, taxes, and non-cash expenses like depreciation and amortization, EBITDA provides insights into the company's core profitability. Investors can analyze the EBITDA data for Alembic Pharmaceuticals Ltd in the financials table or ratio section above for a comprehensive evaluation of the company's financial health.

Alembic Pharmaceuticals Ltd DPS

Dividends Per Share (DPS) is a significant metric for income-seeking investors, reflecting the dividends paid out by Alembic Pharmaceuticals Ltd in relation to its share count. The DPS data for Alembic Pharmaceuticals Ltd can be accessed in the financials table or ratio section above, enabling investors to assess the company's dividend payment history and dividend yield.

Alembic Pharmaceuticals Ltd EPS

Earnings Per Share (EPS) is a widely-used financial metric evaluating Alembic Pharmaceuticals Ltd's profitability on a per-share basis. By dividing the net income by the number of outstanding shares, EPS offers insights into the company's earnings potential and growth trajectory. Visitors can refer to the EPS data for Alembic Pharmaceuticals Ltd in the financials table or ratio section above to understand the company's financial performance in terms of earnings generated for shareholders on a per-share basis.

Alembic Pharmaceuticals Balance Sheet Analysis - An Overview

Alembic Pharmaceuticals Equity and Liabilities Growth

Alembic Pharmaceuticals has shown a steady figure in its share capital over the four years from Mar 2020 to Mar 2024, maintaining at Rs Cr. 39.31 from Mar 2021 onwards. A significant growth in total reserves was noted from Mar 2020's Rs Cr. 3,308.32 to a peak of Rs Cr. 5,251.03 in Mar 2022 before a slight decrease to Rs Cr. 4,869.60 by Mar 2024. The company's borrowings saw a drastic reduction to nil from Mar 2022 onwards, showing a strong financial position with decreased leverage.

Alembic Pharmaceuticals Asset growth and Composition

On the assets front, the net block has progressively expanded from Rs Cr. 1,268.11 in Mar 2020 to Rs Cr. 2,535.66 by Mar 2024, indicating ongoing investments in property, plant, and equipment. However, Capital Work In Progress (WIP) saw a significant reduction from its peak in Mar 2022 at Rs Cr. 2,205.80 to Rs Cr. 524.36 by Mar 2024, reflecting a slowdown in new projects or completion of ongoing ones. Current assets have been on an upward trend reaching Rs Cr. 3,029.74 by Mar 2024, suggestive of strong liquidity.

This data is an analysis for the Standalone Balance sheet of Alembic Pharmaceuticals.

Investors looking into the pharma sector might find Alembic Pharmaceuticals an interesting case study amidst the dynamic landscape of the NSE BSE indices.

Read More
X